Lung injury Market

Lung injury Market Overview 2030

The global lung injury market size was valued at $1,579.47 Million in 2020, and is projected to reach $2,417.41 Million by 2030 registering a CAGR of 4.20% from 2021 to 2030. Lung injury is an inflammatory condition that disrupts the endothelium and epithelial barriers in the lungs. ALI and ARDS are life-threatening forms of respiratory failure characterized by diffuse bilateral lung damage and severe hypoxemia produced by noncardiogenic pulmonary edoema. In addition, it is a key reason of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a significant impact on public health, with high incidence rate across the world. Moreover, it requires administration of rapid and goal-oriented therapy to prevent further lung damage.

The growth of the global lung injury market is majorly driven by rise in prevalence of lung-related diseases and increase in geriatric population. Furthermore, increase in awareness related to treatment of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is expected to notably contribute toward the growth of the global lung injury market. However, complications associated with the use of therapies and low adoption rate due to these complications hinder the market growth. On the contrary, pipeline drugs for the treatment of acute lung injury market are being studied in late phase of clinical trials. . These drugs are likely to be available in the market in next few years, which is expected to offer remunerative opportunity for the expansion of the market during the forecast period.

The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. Moreover, COVID-19 has positively impacted the lung injury market. When COVID-19 was first identified, many researchers redirected their focus to the study of this novel virus and the disease it causes. Severe COVID‐19 represents viral pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, which leads to acute respiratory distress syndrome. Its appearances can be viewed as a combination of the two processes that is viral pneumonia and acute respiratory distress syndrome. SARS‐CoV‐2 represents an ongoing worldwide threat, as this virus family has the potential to mutate and infect non‐immune population. Furthermore, patients with acute respiratory distress syndrome are often incapable to breathe on their own and may require ventilator support to help circulate oxygen in the body. Patients infected with the new coronavirus suffer from severe respiratory failure. For instance, approximately 30% of COVID-19 patients further develop life-threatening acute respiratory distress syndrome resulting in high mortality rate. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome, sepsis & septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Furthermore, older age and comorbid disease patients have been reported as risk factors for death. Till date, no medicine has been approved for the therapeutic treatment of severe COVID-19 and acute respiratory distress syndrome.

Lung Injury Market Segmentation  

The global lung injury market is segmented into therapy, injury type, end user, and region. Depending on therapy, the market is bifurcated into medication and devices. The medication segment is further categorized into pharmacotherapy, fluid management, and inhaled nitric oxide. Moreover, the devices is subdivided into mechanical ventilation and adjunctive procedures devices. On the basis of injury type, the market is segregated into direct injury and indirect injury. By end user, it is fragmented into hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

On the basis of therapy, the medication segment was the major shareholder 2020, as various therapies were used as supportive treatment for lung injury. Depending on injury type, the direct injury acquired the largest share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to rise in incidence of pulmonary infections worldwide.

Snapshot of Asia-Pacific Lung injury market  

Asia-Pacific accounted for the largest share of the global lung injury market in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to the presence of large population base, increase in awareness associated with lung injury treatment, and rise in healthcare expenditure. 

Furthermore, surge in incidence of pulmonary infections in the region, which require the use of medications and devices for treatment of lung injury drives the growth of the market in this region.

List Of Key Companies

• Apeptico Forschung Und Entwicklung GmBH
• Bayer AG
• General Electric Company
• Glaxosmithkline Plc, 
• Koninklijke Philips N.V.
• Linde Plc.
• Medtronic Plc.
• Ony Biotech Inc
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the global lung injury market along with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing lung injury market opportunities.
• Extensive analysis of the key segments of the industry helps to understand the application and products the market used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the lung injury market.

Key Market Segments

By Therapy

• Medication
  • Pharmacotherapy 
  • Fluid Management 
  • Inhaled nitric oxide
• Devices
  • Mechanical Ventilation
  • Adjunctive Procedures Devices 

By Injury Type

• Direct Injury
• Indirect Injury

By End User

• Hospitals & Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China 
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

 Lung injury Market Report Highlights